Phase I Clinical Trial of CBP/Beta-catenin Inhibitor OP-724 in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia. (OP-724-H101)
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Foscenvivint (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
- 08 Oct 2024 New Source Identified and Integrated (Japan Registry of Clinical Trials;jRCT2031200266).
- 07 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2022 Planned End Date changed from 31 Mar 2022 to 31 Mar 2023.